Glioblastoma is also one of the more expensive cancers to treat, often leaving patients and families with major financial hardship on top of the burdens of the disease.Many patients will lose their ability to work, drive, and a host of other functions that contribute to one’s sense of self and independence.In addition to being life-threatening, GBM – and its harsh treatments – inflict devastation upon the brain, which controls cognition, mood, behavior, and every function of every organ and body part.A vast majority of GBM diagnoses are de novo. Some patients have a glioblastoma upon diagnosis (de novo or primary GBM), while other patients’ tumors start as another, lower-grade type of brain tumor and over time progress into a glioblastoma (secondary GBM).None of these treatments have succeeded in significantly extending patient lives beyond a few extra months.Despite first being identified in the scientific literature in the 1920’s, there have only been five drugs and one device ever approved by the FDA for the treatment of glioblastoma.Survival rates and mortality statistics for GBM have been virtually unchanged for decades.The five-year survival rate for glioblastoma patients is only 6.8 percent, and the average length of survival for glioblastoma patients is estimated to be only 8 months.It is estimated that more than 10,000 individuals in the United States will succumb to glioblastoma every year.GBM accounts for 49.1 percent of all primary malignant brain tumors.
More than 13,000 Americans are expected to receive a GBM diagnosis in 2022.Glioblastoma (GBM) is one of the most complex, deadly, and treatment-resistant cancers.Learn more about Glioblastoma Awareness Day Glioblastoma Facts & Figures
0 kommentar(er)
